Bio

Clinical Focus


  • Internal Medicine
  • Geriatrics

Academic Appointments


Administrative Appointments


  • Section Head, Geriatrics, Division of General Medical Disciplines (2015 - Present)
  • Medical Director, Stanford Senior Care Clinic (2014 - Present)
  • Medical Director, Sequoias Portola Valley Heatlh Center (2015 - Present)

Honors & Awards


  • Phi Beta Kappa, Carleton College (1997)
  • Alpha Omega Alpha, UCLA School of Medicine (2003)
  • William B. Valentine Award in Medicine for distinction as a scholar of Internal Medicine, UCLA School of Medicine (2003)
  • Janet M. Glascow Memorial Achievment Citation (for women in top 10% of medical school class), UCLA School of Medicine (2003)
  • Award for Professionalism, Stanford University Department of Medicine, Internal Medicine Residency (2005 and 2006)
  • Physician's Award for Service to the Cardinal Free Clinics, Stanford University School of Medicine (2007)
  • Outstanding Community Preceptor (Pre-clerkship) Award, Stanford University School of Medicine (2010)
  • Advocacy and Community Service Award, Society of General Internal Medicine California-Hawaii Region (2014)

Boards, Advisory Committees, Professional Organizations


  • Member, The American Geriatrics Society (2011 - Present)

Professional Education


  • Residency:Stanford University Hospital -Clinical Excellence Research Center (2006) CA
  • Fellowship:VA Medical Center Palo Alto (2011) CA
  • Board Certification: Geriatric Medicine, American Board of Internal Medicine (2011)
  • Masters in Public Health, UC Berkeley, Epidemiology (2008)
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2006)
  • Medical Education:UCLA School of Medicine (2003) CA
  • BA, Carleton College, Northfield, MN, Neuroscience (1997)

Research & Scholarship

Current Research and Scholarly Interests


Providing quality interdisciplinary care to older patients with complex conditions, dementia, or frailty
Health care delivery in low-income and low English proficiency communities
Improving health care delivery systems for older adults, particularly those with advanced illness and caregiver dependence
Advance care planning

Projects


  • Primary Care 2.0, Stanford Healthcare and Stanford University School of Medicine (9/1/2014)

    on Design Team for reinventing primary care at Stanford

    Location

    Stanford, CA

  • Care Transitions Working Group, Stanford Health Care (2/1/2015)

    Collaborative efforts across Stanford Health Care to support patients in safely and successfully transitiiong to home and rehabilitation facilities

    Location

    Stanford, CA

Publications

All Publications


  • HCV Prevalence in Asian Americans in California. Journal of immigrant and minority health / Center for Minority Public Health Lin, O. N., Chang, C., Lee, J., Do, A., Martin, M., Martin, A., Nguyen, M. H. 2016

    Abstract

    The World Health Organization estimates that 170 million persons are infected with HCV worldwide, but only 22 million are from the Americas and Europe, compared to 94 million from Asia. HCV prevalence in the general US population is 1.6 %, but data for Asian Americans are limited. Our goal was to examine HCV prevalence in Asian Americans in a large ethnically diverse patient cohort seeking primary care at a free clinic in Northern California. A total of 1347 consecutive patients were seen from September 2009 to October 2012 and were studied via individual chart review using case report forms. HCV infection was defined as positive HCV antibody (anti-HCV) or HCV RNA by PCR. 699 out of 1347 patients were screened for HCV. Asian Americans comprised 57.2 % of these patients and 29 (4.1 %) patients tested positive for HCV. Of these 29 HCV-positive patients, 22 (75.9 %) were Asian, yielding a prevalence of 5.5 % for Asians and 2.3 % for non-Asians (P = 0.038). The highest HCV prevalence was seen in Vietnamese patients at 7.9 %, and 6.0 % in Chinese patients. Of the HCV-positive Asians, none had a history of intravenous drug use (IVDU), tattoos, or sexual exposure. On multivariate analysis, significant independent predictors for positive HCV infection were male gender (OR 2.53, P = 0.02) and presence of known risk factors (OR 21.1, P < 0.001). However, older age and Asian ethnicity were found to be significant predictors of HCV infection (OR 1.03, P = 0.05 and 2.31, P = 0.066, respectively). In our study, HCV prevalence in patients seeking routine primary care was 5.5 % in Asian Americans, which was over double the prevalence for non-Asians at 2.3 %. Known risk factors were also notably absent in Asian patients with HCV infection. The high prevalence of HCV in Asian-Americans is likely reflective of the higher prevalence of HCV in their countries of origin in Asia. Asian-Americans immigrants from endemic countries are at higher risk of HCV infection and should be screened for HCV, regardless of their exposure risk profile.

    View details for DOI 10.1007/s10903-016-0342-1

    View details for PubMedID 26798070

  • Chronic Hepatitis B Management Based on Standard Guidelines in Community Primary Care and Specialty Clinics DIGESTIVE DISEASES AND SCIENCES Ku, K. C., Li, J., Ha, N. B., Martin, M., Nguyen, V. G., Nguyen, M. H. 2013; 58 (12): 3626-3633

    Abstract

    Prior studies have underlined the need for increased screening and awareness of chronic hepatitis B (CHB), especially in certain high-risk populations. However, few studies have examined the patterns of evaluation and management of CHB between primary care physicians (PCP) and specialists according to commonly-used professional guidelines. Our goal was to examine whether necessary laboratory parameters used to determine disease status and eligibility for antiviral therapy were performed by PCPs and specialists.We conducted a retrospective study of 253 treatment-naïve CHB patients who were evaluated by PCP only (n = 63) or by specialists (n = 190) for CHB at a community multispecialty medical center between March 2007 and June 2009. Criteria for CHB management and treatment eligibility were based on the American Association for the Study of Liver Diseases 2007 guideline and the US Panel 2006 algorithm. Required parameters for optimal evaluation for CHB included hepatitis B e antigen (HBeAg), HBV DNA, and alanine aminotransferase (ALT). Preferred antiviral agents for CHB included pegylated interferon, adefovir, and entecavir.The majority of patients were Asians (90 %) and male (54 %) with a mean age of 43 ± 11.6 years. Compared to PCPs, specialists were more likely to order laboratory testing for ALT (94 vs. 86 %, P = 0.05), HBeAg (67 vs. 41 %, P < 0.0001) and HBV DNA (83 vs. 52 %, P < 0.0001). The proportion of patients having all three laboratory parameters was significantly higher among those evaluated by specialists compared to PCP (62 vs. 33 %, P < 0.0001). A total of 55 patients were initiated on antiviral treatment (n = 47 by specialists and n = 6 by PCPs). Lamivudine was prescribed more often by PCPs than specialists (33 vs. 2 %, P = 0.05). Preferred agents were used 96 % of the time by specialists compared to 67 % of those treated by PCPs (P = 0.05).Patients evaluated by specialists for CHB are more likely to undergo more complete laboratory evaluation and, if eligible, are also more likely to be treated with preferred longer-term agents for CHB compared to those evaluated by PCPs only. A collaborative model of care involving both PCP and specialists may further optimize management of patients with CHB.

    View details for DOI 10.1007/s10620-013-2889-1

    View details for Web of Science ID 000327456500033

    View details for PubMedID 24122622

  • Consequences of Federal Patient Transfer Regulations: Effect of the 2003 EMTALA Revision on a Tertiary Referral Center and Evidence of Possible Misuse ARCHIVES OF INTERNAL MEDICINE Kao, D. P., Martin, M. H., Das, A. K., Ruoss, S. J. 2012; 172 (11): 891-892

    View details for Web of Science ID 000305087600015

    View details for PubMedID 22688995